[T and B lymphocytes and serum alpha 1-antitrypsin activity in children with bronchial asthma treated with

Related Experiment Video

Updated: Oct 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

J Wartenberg1, J Lewandowska, M Pilarek

  • 1I Katedry i Kliniki Pediatrii AM we Wrocławiu.

Polski Tygodnik Lekarski (Warsaw, Poland : 1960)
|July 16, 1990
PubMed

Insights

Broncho-Vaxom treatment modulated T and B lymphocyte levels in children with asthma. Significant changes in lymphocyte populations correlated with treatment efficacy and serum alpha 1AT activity.

Area of Science:

  • Pediatric Immunology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Asthma is a common chronic respiratory disease in children.
  • Immune system dysregulation plays a role in asthma pathogenesis.
  • Broncho-Vaxom is an immunomodulatory agent used to prevent recurrent respiratory infections.

Purpose of the Study:

  • To assess the impact of Broncho-Vaxom on T and B lymphocyte counts.
  • To evaluate changes in serum alpha-1-antitrypsin (alpha 1AT) levels.
  • To correlate immunological changes with clinical efficacy in pediatric asthma patients.

Main Methods:

  • A clinical trial involving 46 school-aged children with infectious or infectious-atopic asthma.
  • Analysis of T and B lymphocyte percentages before and after Broncho-Vaxom treatment.
  • Measurement of serum alpha 1AT activity.

Main Results:

  • Broncho-Vaxom treatment led to significantly higher T lymphocyte counts in infectious asthma.
  • A significant decrease in B lymphocyte counts was observed in infectious-atopic asthma.
  • Serum alpha 1AT activity decreased significantly in children with infectious asthma.
  • Treatment efficacy correlated with lymphocyte percentage changes, particularly increased T cells and decreased B cells.

Conclusions:

  • Broncho-Vaxom influences T and B lymphocyte populations in pediatric asthma.
  • Immunological shifts, especially T cell increases and B cell decreases, are linked to positive clinical outcomes.
  • Changes in lymphocyte populations are influenced by baseline alpha 1AT levels.

More Related Videos

Murine Model of Allergen Induced Asthma08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...